story of the week
Health-Related Quality-of-Life Outcomes of Treatment With Sacituzumab Govitecan vs Standard Chemotherapy in Patients With Metastatic TNBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer
Eur. J. Cancer 2023 Jan 01;178(2023)23-33, S Loibl, D Loirat, SM Tolaney, K Punie, M Oliveira, HS Rugo, A Bardia, SA Hurvitz, AM Brufsky, K Kalinsky, J Cortés, JA O'Shaughnessy, V Dieras, LA Carey, L Gianni, M Gharaibeh, L Preger, S Phan, L Chang, L Shi, MJ PiccartFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.